Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

aTYR PHARMA INC Director's Dealing 2022

May 26, 2022

34337_dirs_2022-05-26_4cce4839-429c-4639-9560-2ebdba0a483b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2022-05-24

Reporting Person: Broadfoot Jill Marie (Chief Financial Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-05-24 Employee Stock Option (right to buy) $2.81 A 75347 Acquired 2032-05-24 Common Stock (75347) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 12290 Direct

Footnotes

F1: Includes 178 shares acquired under the Company's 2015 Employee Stock Purchase Plan (ESPP) on May 13, 2022.

F2: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning June 24, 2022, such that this option will be fully exercisable on May 24, 2026. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.